Drug
XEN1101
XEN1101 is a pharmaceutical drug with 6 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
2
33%
Ph phase_3
4
67%
Phase Distribution
0
Early Stage
2
Mid Stage
4
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
4(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
6
all time
Status Distribution
Active(4)
Completed(2)
Detailed Status
Completed2
Recruiting2
Enrolling by invitation1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 22 (33.3%)
Phase 34 (66.7%)
Trials by Status
enrolling_by_invitation117%
completed233%
active_not_recruiting117%
recruiting233%
Recent Activity
3 active trials
Showing 5 of 6
enrolling_by_invitationphase_3
An Open-label Study of XEN1101 in Epilepsy
NCT05718817
completedphase_3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05614063
recruitingphase_3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100
recruitingphase_3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142
completedphase_2
XEN1101 for Major Depressive Disorder
NCT04827901
Clinical Trials (6)
Showing 6 of 6 trials
NCT05718817Phase 3
An Open-label Study of XEN1101 in Epilepsy
NCT05614063Phase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
NCT05716100Phase 3
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05667142Phase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT04827901Phase 2
XEN1101 for Major Depressive Disorder
NCT03796962Phase 2
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6